PMPRB adopts Amended Interim Guidance pending release of new guidelines | Smart & Biggar

As previously reported, the Patented Medicine Prices Review Board (PMPRB) proposed amendments in June 2023 to its Interim Guidance (“Amended Interim Guidance”) for reviewing the prices...

Related Keywords

Canada , ,Patented Medicine Prices Review Board ,Interim Guidance ,Patented Medicines ,Amended Interim Guidance ,Maximum Average Potential Price ,Non Excessive Average Price ,New Medicines ,Interim Period ,